Devices for mechanical circulatory support have become, over recent years, the main parts in the treatment of cardiogenic shock and in the maintenance of circulatory support for patients with terminal heart failure. The use of these devices has been widely indicated as a bridge for subsequent heart transplantation, as supportive treatment for the recovery of the heart in acute myocardial infarction and postoperative cardiac surgery, or even to allow for ventricular recovery during rest obtained by prolonged mechanical circulatory support in patients with cardiomyopathies [1,2]. Additionally, mechanical devices to assist the left ventricle have been deployed in some countries, as destination therapy in the treatment of patients with terminal heart failure with contraindications to cardiac transplantation [1,2].
The development of cardiac surgery in Brazil has always been characterized by the incorporation of latest technologies and treatments in many different fields. In addition, the specialty currently includes a large number of procedures performed, mainly in the treatment of coronary disease [3,4]. Moreover, the use of mechanical assist devices has been limited in our country to support postoperative patients undergoing cardiac surgery by use of centrifugal pumps and some unique experiments with the use of cardiopulmonary bypass with membrane oxygenator (ECMO) in the postoperative period of pediatric cardiac surgery  or the treatment of cardiogenic shock after myocardial infarction . Similarly, the use of mechanical assist devices as bridge to heart transplantation also can be summed up in few cases performed [7,8].
Despite the long history of heart transplantation in Brazil  and the promising results observed with this therapy, especially in the treatment of Chagas' heart disease , a major limitation noted for the results of this procedure is the high mortality observed in the waiting list. Data from the State System of Transplantation of São Paulo showed that 50% of patients listed for heart transplantation over the past five years died on the waiting list. The incidence of cardiogenic shock due to progressive circulatory failure is the leading cause of mortality in patients with advanced cardiomyopathy. In this condition, the mortality rate can reach values above 60% at six months follow-up may be even higher in patients with Chagas' heart disease [11,12]. The incidence of cardiogenic shock is also the leading cause of mortality on the waiting list for heart transplantation in pediatric patients. Whit respect this, Jatene et al.  reported a transplantation performed in only eight of 22 children with dilated cardiomyopathy, aged 11 months to 11 years who developed this complication and were treated medically.
Because of the high mortality observed in the presence of ventricular failure, the use of mechanical circulatory assist devices is, in most cases, the only chance of survival while waiting for a donor. Various types of devices have been used to serve as a bridge to cardiac transplantation and international experience with this type of therapy sums up to thousands of cases [1,2]. Based on this experience, the indications of mechanical circulatory support is well established  as well as the impact of applying this therapy on life expectancy of patients .
In our country, the management of patients who develop cardiogenic shock due to the irreversible impairment of ventricular myocardium continues to rely solely on the use of drug therapy [16,17]. Despite the incorporation of new drugs to control this complication, mortality remains high, reducing the life expectancy of patients and the likelihood of receiving a heart transplant .
In parallel, the Brazilian experience with the use of mechanical circulatory support as bridge to transplantation adds a little more than a dozen cases in which paracorporeal ventricular assist devices were used in periods ranging from several days to about two months of circulatory support [7,8]. From this experience, we highlight the pioneering use of mechanical circulatory assist devices in patients with Chagas' heart disease .
Despite the existence of well-established indication criteria in national guidelines for treatment of heart failure , the lack of financial support by the agencies responsible for health care in Brazil avoids the access of patients to the use of mechanical devices to treat acute circulatory failure. On the other hand, other high-cost treatments have been funded by the National Health System and the private sector, as the use of ventricular resynchronizers and implantable defibrillators for treating heart failure [20-22].
Cost-effectiveness studies in several countries about the impact of the use of mechanical circulatory support in the treatment of progressive circulatory failure, show values ranging between. $48,000.00 (R$ 86,000.00) and $90,000.00 (R$ 160,000.00) per year of life saved and qualityadjusted (quality adjusted life years - QALY) . In these studies it was not considered the type of device used, and it could be possible to anticipate values near the lower limit for the use of paracorporeal devices when comparing with implantable devices widely used in several centers worldwide. Similar values as those of mechanical support were observed for the use of cardiac resynchronization therapy defibrillator implantation combined with a systematic review that included data from more than 3,400 patients . In parallel, a study about the isolated use of defibrillators in heart failure patients in our country showed a ratio of incremental cost-effectiveness of R $ 68,000.00 in the public and R $ 90,000.00 in the private sector .
Based on these data, we conclude that despite the high cost of treatment of cardiovascular diseases in Brazil in relation to our income per capita , we certainly have reasons to incorporate as a therapeutic option the device implantation of mechanical circulatory support, primarily as bridge to heart transplantation. This procedure is responsible for higher survival rates of 70% in one year, opening the prospect of performing a transplant in most patients treated.
1. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29(1):1-10. [MedLine]
2. Shreenivas SS, Rame JE, Jessup M. Mechanical circulatory support as a bridge to transplant or for destination therapy. Curr Heart Fail Rep. 2010;7(4):159-66. [MedLine]
3. Lisboa LA, Moreira LF, Mejia OV, Dallan LA, Pomerantzeff PM, Costa R, et al. Evolution of cardiovascular surgery at the Instituto do Coração: analysis of 71,305 surgeries. Arq Bras Cardiol. 2010;94(2):162-8.
4. Piegas LS, Bittar OJ, Haddad N. Myocardial revascularization surgery (MRS): results from national health system (SUS). Arq Bras Cardiol. 2009;93(5):555-60. [MedLine]
5. Atik FA, Castro RS, Succi FM, Barros MR, Afiune C, Succi GM, et al. Use of centrifugal pump and extracorporeal membrane oxygenation as cardiopulmonary support in pediatric cardiovascular surgery. Arq Bras Cardiol. 2008;90(4):216-20. [MedLine]
6. Colafranceschi AS, Monteiro AJ, Canale LS, Campos LA, Montera MW, Silva PR, et al. Adult extracorporeal life support: a failed or forgotten concept? Arq Bras Cardiol. 2008;91(1):34-41. [MedLine]
7. Colafranceschi AS, Monteiro AJ, Barbosa RM, Côrtes DC, Correa CM, Canale LS, et al. Use of mechanical circulatory support in cases of end-stage acute heart failure. Arq Bras Cardiol. 2007;89(5):311-4.
8. Galantier J, Moreira LF, Benício A, Leirner AA, Cestari I, Bocchi EA, et al. Hemodynamic performance and inflammatory response during the use of VAD-InCor as a bridge to transplant. Arq Bras Cardiol. 2008;91(5):327-34. [MedLine]
9. Rodrigues da Silva P. Cardiopulmonary and heart transplantation: 100 years of history and 40 years of existence. Rev Bras Cir Cardiovasc. 2008;23(1):145-52. [MedLine] View article
10. Bacal F, Silva CP, Pires PV, Mangini S, Fiorelli AI, Stolf NG, et al. Transplantation for Chagas disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transplant. 2010;24(2):E29-34.
11. Moreira LF, Galantier J, Benício A, Leirner AA, Fiorelli AI, Stolf NA, et al. Perspectivas da evolução clínica de pacientes com cardiomiopatia chagásica listados em prioridade para o transplante cardíaco. Rev Bras Cir Cardiovasc. 2005;20(3):261-9. View article
12. Silva CP, Del Carlo CH, Oliveira Junior MT, Scipioni A, Strunz-Cassaro C, Ramirez JA, et al. Why do patients with chagasic cardiomyopathy have worse outcomes than those with non-chagasic cardiomyopathy? Arq Bras Cardiol. 2008;91(6):358-62. [MedLine]
13. Jatene MB, Miana LA, Pessoa AJ, Riso A, Azeka E, Tanamati C, et al. Pediatric heart transplantation in refractory cardiogenic shock: a critical analysis of feasibility, applicability and results. Arq Bras Cardiol. 2008;90(5):329-33. [MedLine]
14. Wilson SR, Mudge GH Jr, Stewart GC, Givertz MM. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation. 2009;119(16):2225-32. [MedLine]
15. Boilson BA, Raichlin E, Park SJ, Kushwaha SS. Device therapy and cardiac transplantation for end-stage heart failure. Curr Probl Cardiol. 2010;35(1):8-64. [MedLine]
16. Bocchi EA, Vilas-Boas F, Moreira MC, Barretto AC, Lage S, Albuquerque D, Investigators of BELIEF Study; Heart Failure Working Group of Brazilian Society of Cardiology. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Arq Bras Cardiol. 2008;90(3):182-90. [MedLine]
17. Mangini S, Silveira FS, Silva CP, Grativvol PS, Seguro LF, Ferreira SM, et al. Decompensated heart failure in the emergency department of a cardiology hospital. Arq Bras Cardiol. 2008;90(6):400-6. [MedLine]
18. Barretto AC, Del Carlo CH, Cardoso JN, Morgado PC, Munhoz RT, Eid MO, et al. Hospital readmissions and death from Heart Failure: rates still alarming. Arq Bras Cardiol. 2008;91(5):335-41. [MedLine]
19. Montera MW, Almeida RA, Tinoco EM, Rocha RM, Moura LZ, Réa-Neto A, et al. Sociedade Brasileira de Cardiologia. II Diretriz Brasileira de Insuficiência Cardíaca Aguda. Arq Bras Cardiol.2009;93(3 supl.3):1-65
20. Silva RT, Martinelli Filho M, Lima CE, Martins DG, Nishioka SA, Pedrosa AA, et al. Functional behavior of patients with conventional pacemakers undergoing cardiac resynchronization. Arq Bras Cardiol. 2008;90(2):138-43. [MedLine]
21. Veiga VC, Abensur H, Rojas SS. Echocardiography in cardiac resynchronization therapy. Arq Bras Cardiol. 2009;93(4):441-5.
22. Hadid C, Avellana P, Di Toro D, Gomez CF, Visser M, Prieto N. Long-term follow-up of patients with indication for a implantable defibrillator for primary prevention of death. Arq Bras Cardiol. 2008;90(5):311-5. [MedLine]
23. Hutchinson J, Scott DA, Clegg AJ, Loveman E, Royle P, Bryant J, et al. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. Expert Rev Cardiovasc Ther. 2008;6(2):175-85. [MedLine]
24. Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess. 2007;11(47):iii-iv, ix-248. [MedLine]
25. Ribeiro RA, Stella SF, Zimerman LI, Pimentel M, Rohde LE, Polanczyk CA. Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors. Arq Bras Cardiol. 2010;95(5):577-86. [MedLine]
26. Azambuja MI, Foppa M, Maranhão MF, Achutti AC. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arq Bras Cardiol. 2008;91(3):148-55.